ALSO NOTED: Cell Therapeutics seeks SPA for lymphoma trial; Panacos agrees to try dose-escalation in HIV trial;and much more...

> Cell Therapeutics is working on a Special Protocol Assessment with the FDA for a late-stage trial of its therapy for non-Hodgkin's lymphoma. Report

> Panacos has agreed with the FDA on a dose-escalation approach in its next study of bevirimat for HIV. Report

> Cellzome announced that it has received the first milestone payment for its Gamma Secretase Modulator program in connection with the selection of a lead compound by Ortho-McNeil Pharmaceutical. Release

> GTC Biotherapeutics and PharmAthene have inked a deal providing PharmAthene an expanded license to GTC's patent rights, which will support the further development and commercialization of PharmAthene's Protexia program. Release

> Transgene has won exclusive access to Virax's Co-X-Gene technology patents for use in two of Transgene's immunotherapeutic products, TG4010 and TG4001. Release

> A group of three universities has banded together to create a research grid that will allow cardiovascular researchers to share data, analytical tools and models on healthy and diseased patients. Report

> Investigating the composition and behavior of microscale environments, including those within living cells, could become easier and more precise with nanoelectrodes being developed at the University of Illinois. Report

And Finally... While cautioning against racial stereotyping, researchers say that African-Americans and other minorities in the U.S. are more likely than whites to keep fighting terminal illnesses, seeking out the most aggressive treatments available. Report

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.